Daily Health
·23/03/2026
When you take a medication, you trust that it’s safe and effective. But have you ever considered where it was developed? For decades, the world’s drug discovery engine has been concentrated in North America, Europe, and Asia. While this model has produced countless life-saving treatments, a new, more localized approach is emerging, highlighting that a one-size-fits-all solution isn’t always best for global health.
Let's compare the established model with the pioneering work happening in places like Africa to understand why this shift is so critical.
The traditional drug discovery pipeline, primarily in the Global North, is a powerhouse. Fueled by massive investment and vast infrastructure, pharmaceutical companies and research institutions can screen tens of thousands of molecules to find promising drug candidates. This system excels at tackling health challenges relevant to its populations.
However, its focus is naturally guided by the health priorities and markets of wealthier nations. Diseases that disproportionately affect the Global South, such as malaria and tuberculosis, may receive less attention. Furthermore, clinical trials are often conducted on populations that are not genetically diverse, which can have serious implications for a drug's effectiveness and safety elsewhere.
In contrast, centers like the Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town are flipping the script. Founded by scientist Kelly Chibale, this facility is dedicated to discovering drugs for diseases prevalent on the African continent.
The scientific process is just as rigorous, involving the meticulous testing of molecules to find ones that kill a parasite without harming human cells. The crucial difference is the context. By focusing on local diseases and populations, these researchers address urgent, unmet needs. This approach also helps build scientific capacity and retain brilliant minds in Africa, creating a sustainable ecosystem for innovation.
The most compelling reason for localized research lies in our DNA. Africa is the most genetically diverse continent on Earth. This means different populations can metabolize, or process, the same drug in vastly different ways. A dose that is safe and effective for a person in North America could be toxic or useless for someone in Zambia.
Scientists determine correct dosages by studying how the liver breaks down drugs. Since this varies across populations, research must be conducted with the target population in mind. When local data is scarce, as it can be in Africa, scientists at H3D are developing innovative solutions, like using computer models to predict how a drug will behave in diverse African populations.
Ultimately, the rise of Africa-led drug discovery isn't about replacing the old model but enhancing it. It proves that to create truly global health solutions, the research must also be global, ensuring that the medicines of tomorrow are safe and effective for everyone, no matter where they live.









